Scholarlink

Background <p>Human papillomavirus (HPV)-related diseases have risen in Japan since recommendations for the HPV vaccine were suspended in 2013. This study evaluated the public health benefit of extending the current 3-year nonavalent HPV (9vHPV) catch-up vaccination program for females 17–26 years of age to 6 years.</p> Methods <p>A dynamic transmission model calibrated to Japanese specific demographic and epidemiological data compared the impact of different 9vHPV vaccination scenarios on female and male HPV-related diseases over a 100-year time horizon. The base-case analysis compared the routine vaccination in combination with the current 3-year catch-up program for females 17–26 years of age from 2022 to 2025 (status quo) to the routine vaccination in combination with an extended 6-year program from 2022 to 2028 (6-year catch-up scenario) for Japan.</p> Results <p>HPV-related disease incidence with the 6-year catch-up scenario decreased further than the status quo over 100 years. Extending catch-up vaccinations from three to six years in combination with routine vaccination prevented an additional 413,454 HPV-related disease cases and 7,184 deaths for both sexes. Anogenital warts had the highest number of averted cases (361,020 cases) and males (229,867 cases) had more total HPV-related disease cases averted than females (183,586 cases).</p> Conclusions <p>Routine vaccination in combination with an extension of the catch-up HPV vaccination strategy for females 17–26 years of age from three to six years may expedite the decrease of morbidity and mortality due to HPV-related diseases in Japan.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The public health impact of extending the catch-up nonavalent human papillomavirus vaccination program to 2028 in Japan: a model-based study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月6日

查看全文
  • Ibrahim Diakite,
  • Keisuke Tobe,
  • Xuedan You,
  • Ya-Ting Chen,
  • Cody Palmer,
  • Taizo Matsuki

摘要

Background

Human papillomavirus (HPV)-related diseases have risen in Japan since recommendations for the HPV vaccine were suspended in 2013. This study evaluated the public health benefit of extending the current 3-year nonavalent HPV (9vHPV) catch-up vaccination program for females 17–26 years of age to 6 years.

Methods

A dynamic transmission model calibrated to Japanese specific demographic and epidemiological data compared the impact of different 9vHPV vaccination scenarios on female and male HPV-related diseases over a 100-year time horizon. The base-case analysis compared the routine vaccination in combination with the current 3-year catch-up program for females 17–26 years of age from 2022 to 2025 (status quo) to the routine vaccination in combination with an extended 6-year program from 2022 to 2028 (6-year catch-up scenario) for Japan.

Results

HPV-related disease incidence with the 6-year catch-up scenario decreased further than the status quo over 100 years. Extending catch-up vaccinations from three to six years in combination with routine vaccination prevented an additional 413,454 HPV-related disease cases and 7,184 deaths for both sexes. Anogenital warts had the highest number of averted cases (361,020 cases) and males (229,867 cases) had more total HPV-related disease cases averted than females (183,586 cases).

Conclusions

Routine vaccination in combination with an extension of the catch-up HPV vaccination strategy for females 17–26 years of age from three to six years may expedite the decrease of morbidity and mortality due to HPV-related diseases in Japan.